Literature DB >> 30275094

Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.

Tim R Cressey1,2,3, Linda Harrison4, Jullapong Achalapong5, Prateep Kanjanavikai6, Orada Patamasingh Na Ayudhaya7, Prateung Liampongsabuddhi8, Thitiporn Siriwachirachai9, Chaiwat Putiyanun10, Pornnapa Suriyachai11, Camlin Tierney4, Nicolas Salvadori12, Dujrudee Chinwong13, Luc Decker14, Yardpiroon Tawon12, Trudy V Murphy15, Nicole Ngo-Giang-Huong12,2,14, George K Siberry16, Gonzague Jourdain12,2,13.   

Abstract

We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC0-24]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC0-24 was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  hepatitis B virus; pharmacokinetics; pregnancy; tenofovir

Mesh：

Substances：

Year:  2018        PMID： 30275094      PMCID： PMC6256809          DOI： 10.1128/AAC.01686-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

2.  Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B.

Authors:  Gonzague Jourdain; Nicole Ngo-Giang-Huong; Linda Harrison; Luc Decker; Woottichai Khamduang; Camlin Tierney; Nicolas Salvadori; Tim R Cressey; Wasna Sirirungsi; Jullapong Achalapong; Prapap Yuthavisuthi; Prateep Kanjanavikai; Orada P Na Ayudhaya; Thitiporn Siriwachirachai; Sinart Prommas; Prapan Sabsanong; Aram Limtrakul; Supang Varadisai; Chaiwat Putiyanun; Pornnapa Suriyachai; Prateung Liampongsabuddhi; Suraphan Sangsawang; Wanmanee Matanasarawut; Sudanee Buranabanjasatean; Pichit Puernngooluerm; Chureeratana Bowonwatanuwong; Thanyawee Puthanakit; Virat Klinbuayaem; Satawat Thongsawat; Sombat Thanprasertsuk; George K Siberry; Diane H Watts; Nahida Chakhtoura; Trudy V Murphy; Noele P Nelson; Raymond T Chung; Stanislas Pol; Nantasak Chotivanich
Journal:  N Engl J Med       Date:  2018-03-08       Impact factor: 91.245

3.  The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.

Authors:  Angela P H Colbers; David A Hawkins; Andrea Gingelmaier; Kabamba Kabeya; Jürgen K Rockstroh; Christopher Wyen; Katharina Weizsäcker; S Tariq Sadiq; Jelena Ivanovic; Carlo Giaquinto; Graham P Taylor; José Moltó; David M Burger
Journal:  AIDS       Date:  2013-03-13       Impact factor: 4.177

4.  Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.

Authors:  Sihem Benaboud; Déborah Hirt; Odile Launay; Emmanuelle Pannier; Ghislaine Firtion; Elisabeth Rey; Naïm Bouazza; Frantz Foissac; Hélène Chappuy; Saik Urien; Jean Marc Tréluyer
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

5.  Pharmacokinetics of tenofovir during pregnancy and postpartum.

Authors:  B M Best; S Burchett; H Li; A Stek; C Hu; J Wang; E Hawkins; M Byroads; D H Watts; E Smith; C V Fletcher; E V Capparelli; M Mirochnick
Journal:  HIV Med       Date:  2015-05-11       Impact factor: 3.180

6.  Clinical pharmacology quality assurance for HIV and related infectious diseases research.

Authors:  R DiFrancesco; K Tooley; S L Rosenkranz; S Siminski; C R Taylor; P Pande; G D Morse
Journal:  Clin Pharmacol Ther       Date:  2013-03-26       Impact factor: 6.875

7.  Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention.

Authors:  Wan-Hsin Wen; Mei-Hwei Chang; Lu-Lu Zhao; Yen-Hsuan Ni; Hong-Yuan Hsu; Jia-Feng Wu; Pei-Jer Chen; Ding-Shinn Chen; Huey-Ling Chen
Journal:  J Hepatol       Date:  2013-02-26       Impact factor: 25.083

Review 8.  Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.

Authors:  Brian P Kearney; John F Flaherty; Jaymin Shah
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.

Authors:  Wasna Sirirungsi; Saik Urien; Linda Harrison; Jiraporn Kamkon; Yardpiroon Tawon; Nuananong Luekamlung; Suchart Thongpaen; Ampaipith Nilmanat; Gonzague Jourdain; Marc Lallemant; Sophie Le Coeur; Nicole Ngo-Giang-Huong; Andrew Owen; Tim R Cressey
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-01       Impact factor: 3.731

10.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17
View more
  7 in total

1.  Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.

Authors:  Calvin Q Pan; Ting-Tsung Chang; Si Hyun Bae; Maurizia Brunetto; Wai-Kay Seto; Carla S Coffin; Susanna K Tan; Shuyuan Mo; John F Flaherty; Anuj Gaggar; Mindie H Nguyen; Mustafa Kemal Çelen; Alexander Thompson; Edward J Gane
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

2.  Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.

Authors:  Ahizechukwu C Eke; Kensuke Shoji; Brookie M Best; Jeremiah D Momper; Alice M Stek; Tim R Cressey; Mark Mirochnick; Edmund V Capparelli
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.938

3.  Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus.

Authors:  Geoffroy Liegeon; Nicole Ngo-Giang-Huong; Nicolas Salvadori; Piyawan Bunpo; Ratchada Cressey; Jullapong Achalapong; Prateep Kanjanavikai; Orada Patamasingh Na Ayudhaya; Sinart Prommas; Thitiporn Siriwachirachai; Prapan Sabsanong; Jean Yves Mary; Gonzague Jourdain
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.758

4.  Early Start Of Tenofovir Treatment Achieves Better Viral Suppression In Pregnant Women With A High HBV Viral Load: A Real-World Prospective Study.

Authors:  Fan Gao; Wen-Tao Zhang; Ya-Yun Lin; Wei-Min Wang; Na Xu; Gui-Qin Bai
Journal:  Infect Drug Resist       Date:  2019-11-07       Impact factor: 4.003

5.  Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study.

Authors:  Sisi Yang; Xueqing Ma; Chengwei Cai; Huanqiu Wang; Fenqiang Xiao; Chengbo Yu
Journal:  Front Med (Lausanne)       Date:  2021-03-15

6.  Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.

Authors:  Lynda Stranix-Chibanda; Peter L Anderson; Deborah Kacanek; Sybil Hosek; Sharon Huang; Teacler G Nematadzira; Frank Taulo; Violet Korutaro; Clemensia Nakabiito; Maysebole Masenya; Kathryn Lypen; Emily Brown; Mustafa E Ibrahim; Jenna Yager; Lubbe Wiesner; Benjamin Johnston; K Rivet Amico; James F Rooney; Nahida Chakhtoura; Hans M L Spiegel; Benjamin H Chi
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 20.999

7.  Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.

Authors:  Vera E Bukkems; Elise J Smolders; Gonzague Jourdain; David M Burger; Angela P Colbers; Tim R Cressey
Journal:  J Clin Pharmacol       Date:  2020-09-22       Impact factor: 3.126
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.